Business Context and Reporting Period
Company: Senseonics Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 10, 2016
Event: Announcement of regulatory approval for the Eversense CGM System.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes
The material change reported is the receipt of CE Mark approval for the Eversense CGM System. This system is described as the first and only long-term, implantable continuous glucose monitoring system for people with diabetes.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the CE Mark approval.
Forward-Looking Statements: The Company disclaims any obligation to update the information contained in this report in the future, except as required by applicable law.
Investor Verification Checklist
- Verify the specific scope and limitations of the CE Mark approval for the Eversense CGM System.
- Review the full text of the press release attached as Exhibit 99.1 for additional details on commercialization plans.
- Consult the Company's most recent 10-K or 10-Q filings for current financial performance and liquidity status, as this 8-K does not contain such data.